OncoMatch/Clinical Trials/NCT06616597
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Is NCT06616597 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Abiraterone acetate and Dexamethasone for prostate cancer (adenocarcinoma).
Treatment: Abiraterone acetate · Dexamethasone · Metronidazole — To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: abiraterone (abiraterone, prednisone)
PSA (+/- radiographic) progression after having been on abiraterone and prednisone for at least 12 weeks.
Must have received: LHRH agonist or orchiectomy
Must be maintained on a GnRH analogue or have undergone orchiectomy.
Cannot have received: investigational therapeutic or invasive surgical procedure (not including surgical castration)
Administration of an investigational therapeutic or invasive surgical procedure (not including surgical castration) within 30 days of Cycle 1 Day 1 or currently enrolled in an investigational drug study
Cannot have received: antibacterial therapy
On antibacterial therapy within 30 days prior to administration of study treatment.
Lab requirements
Liver function
Chronic liver disease with Child-Pugh class C cirrhosis; Bilirubin >3x ULN or AST and ALT >5x ULN
Cardiac function
Congenital prolonged QTc syndrome or QTc > 500 msec (non-paced rhythm)
Chronic liver disease with Child-Pugh class C cirrhosis (see calculator in protocol); Bilirubin >3x ULN or AST and ALT >5x ULN; Congenital prolonged QTc syndrome or QTc > 500 msec (non-paced rhythm)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06616597 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational therapeutic or invasive surgical procedure (not including surgical castration), antibacterial therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages